I am a Healthcare Professional outside the US and UK

I am a Healthcare Professional outside the US and UK

Click here for international medical scientific information about Oncology for Healthcare Professionals.

I am not a Healthcare Professional and I am outside the US and the UK

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information for patients, caregivers and the general public.

Country-specific medical scientific information

Country-specific medical scientific information

Country-specific medical scientific information for Healthcare Professionals.

This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

InOncology.com
Welcome to
InOncology.com

A knowledge hub developed to provide information and education in oncology for healthcare professionals.

Rate this

Our activities at WCLC 2019

7–10 September 2019
Barcelona, Spain
Booth #307
6 Publications
1 Symposium

Our activities at ESMO 2019

27 September–1 October 2019
Barcelona, Spain
Booth #401
1 Symposium
GioTag study update: now published

GioTag study update: real-world data on sequential therapy in NSCLC

CRC in focus: information and hot topics

CRC in focus: information and hot topics

SIRPα myeloid checkpoint inhibitor mechanism of action

Learn about our investigational SIRPα myeloid checkpoint inhibitor§

InOncology Slide Bank

An educational resource created in a spirit of collaboration to share materials across key tumour types and topics of interest in oncology. Explore the new modules on real-world evidence and molecular testing.

LUX-Head & Neck 3 Clinical Trial

Read the recently reported results of LUX-Head and Neck 3 – a trial that investigated afatinib§ as second-line treatment in Asian patients with HNSCC

InOncology article library

Search this library for published papers about afatinib and nintedanib¶

Nintedanib after ICI therapy

Learn more about emerging data from the VARGADO study
Physicians’ insights
Nicolas Girard
Prof Nicolas Girard

Prolonging the chemotherapy-free period in EGFRM+ NSCLC

FIND OUT MORE
image
Dr Maximilian Hochmair

Sequencing in EGFR-mutated NSCLC: does order matter?

FIND OUT MORE
Edward S. Kim
Dr Edward Kim

Efficacy of EGFR TKIs in patients with uncommon mutations

FIND OUT MORE
The role of EGFR TKIs in the treatment of squamous NSCLC
Dr David Gandara

Maximising the clinical potential of TKIs for patients with squamous NSCLC

FIND OUT MORE
Squamous NSCLC: where do EGFR TKIs fit in?
Dr Noemi Reguart

The challenge of preventing and managing brain metastases in EGFRm+ NSCLC

FIND OUT MORE
Professor Martin Schuler
Prof Martin Schuler

Improving outcomes for patients with brain metastases

FIND OUT MORE
Prof Reck discusses recent changes and sequencing strategies in non mutated, non-squamous advanced NSCLC
Prof Martin Reck

Recent changes and sequencing strategies in non-mutated, non-squamous advanced NSCLC

FIND OUT MORE
Sanjay Popat
Dr Sanjay Popat

Treating second-line and beyond in non-mutated, non-squamous NSCLC: now and tomorrow

FIND OUT MORE
Barbara Melosky
Dr Barbara Melosky

Clinical considerations in EGFRm+ NSCLC: does treatment sequence matter?

FIND OUT MORE
Vanesa Gregorc
Prof Vanesa Gregorc

Sequencing algorithms in NSCLC

FIND OUT MORE
Professor Nir Pelend discusses treatment strategies in EGFRm+ NSCLC
Prof Nir Peled

Treatment strategies in EGFRm+ NSCLC

FIND OUT MORE
<
>

*This is an investigational compound and has not been approved. Its safety and efficacy have not been established.

§Afatinib is approved in more than 80 markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list, please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information, please click here. Nintedanib is not approved in other oncology indications.